Inhalation therapies in acute respiratory distress syndrome

Area of Science:

• Pulmonary Medicine
• Critical Care Medicine
• Pharmacology

Background:

• Acute respiratory distress syndrome (ARDS) is characterized by severe lung inflammation, high mortality, and limited treatment options.
• Current treatments focus on supportive care and preventing further lung injury, but do not reverse the underlying pathology.
• Translating promising preclinical drug findings to ARDS patients has been challenging.

Purpose of the Study:

• To review the effects of various aerosolized drugs for ARDS prevention and treatment.
• To explore novel therapeutic strategies, including inhaled medications and emerging agents.
• To assess the potential of direct lung delivery to minimize systemic adverse events.

Main Methods:

• Analysis of existing literature on aerosolized bronchodilators, corticosteroids, pulmonary vasodilators, anticoagulants, mucolytics, and surfactant.
• Review of ongoing clinical trials and preclinical data for new therapies such as carbon monoxide (CO) and AP301 peptide.
• Evaluation of inhalation and nebulization as direct drug delivery methods to the lungs.

Main Results:

• Inhaled medications offer a promising route for ARDS management by targeting the lungs directly.
• Preclinical successes of pharmacological agents have not consistently translated to clinical efficacy in ARDS.
• Emerging strategies like CO and AP301 peptide show potential for future ARDS therapeutic interventions.

Conclusions:

• Direct aerosolized drug delivery to the lungs is a key strategy to prevent ARDS progression and reduce systemic toxicity.
• Further research and clinical trials are essential to validate novel inhaled therapies and agents like CO and AP301 peptide for ARDS.
• Developing effective pharmacological interventions remains critical to improve outcomes for patients with ARDS.